Comparative examination of anti-proliferative activities of (-)-epigallocatechin gallate and (-)-epigallocatechin against HCT116 colorectal carcinoma cells

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 1, 2008, Pages 79-84

  Inaba, Hiroyuki ^a   Nagaoka, Yasuo ^a   Kushima, Yukihiro ^a   Kumagai, Ayako ^a   Matsumoto, Yoshinori ^a   Sakaguchi, Minoru ^b   Baba, Kimiye ^b   Uesato, Shinichi ^a  

^a KANSAI UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

( ) epigallocatechin; ( ) epigallocatechin gallate; Apoptosis; Confluency; HCT116 colorectal carcinoma cell; Mitogen activated protein kinase

Indexed keywords

EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CATECHIN; CELL CYCLE; CELL PROLIFERATION; HCT116 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 37849009071     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.79     Document Type: Article

References (23)

1. Ahmad N., Feyes D. K., Nieminen A. L., Agarwal R., Mukhtar H., J. Natl. Cancer Inst., 89, 1881-1886 (1997).
2. Chen Z. P., Schell J. B., Ho C. T., Chen K. Y., Cancer Lett., 129, 173-179 (1998).
3. Khafif A., Schantz S. P., Chou T. C., Edelstein D., Sacks P. G., Carcinogenesis, 19, 419-424 (1998).
4. Yang G. Y., Liao J., Kim K., Yurkow E. J., Yang C. S., Carcinogenesis, 19, 611-616 (1998).
5. Chen L., Lee M. J., Li H., Yang C. S., Drug Metab. Dispos., 25, 1045-1050 (1997).
6. Kim S., Lee M. J., Hong J., Li C., Smith T. J., Yang G.-Y., Seril D. N., Yang C. S., Nutr. Cancer, 37, 41-48 (2000).
7. Suganuma M., Okabe S., Oniyama M., Tada Y., Ito H., Fujiki H., Carcinogenesis, 19, 1771-1776 (1998).
8. Yang C. S., Chung J. Y., Yang G., Chhabra S. K., Lee M. J., J. Nutr., 130, 472S-478S (2000).
9. Lee M.-J., Maliakal P., Chen L., Meng X., Bondoc F. Y., Prabhu S., Lambert G., Mohr S., Yang C. S., Cancer Epidemiol. Biomarkers Prev., 11, 1025-1032 (2002).
10. Lu H., Meng X., Li C., Sang S., Patten C., Sheng S., Hong J., Bai N., Winnik B., Ho C.-T., Yang C. S., Drug Metab. Dispos., 31, 452-461 (2003).
11. Yamashita S., Sakane T., Harada M., Sugiura N., Koda H., Kiso Y., Sezaki H., Ann. N.Y. Acad. Sci., 957, 325-328 (2002).
12. Immunochemistry Protocols for use with Innovative Antibody Products by Covance Research Products. http://store.crpinc.com/prot_western.aspx
13. Maeda T., Nagaoka Y., Kuwajima H., Seno C., Maruyama S., Kaurotaki M., Uesato S., Bioorg. Med. Chem., 12, 4351-4360 (2004).
14. Chen C., Shen G., Hebbar V., Hu R., Owuor E. D., Kong A. N. T., Carcinogenesis, 24, 1369-1378 (2003).
15. Yu R., Jiao J. J., Duh J. L., Gudehithlu K., Tan T. H., Kong A. N., Carcinogenesis, 18, 451-456 (1997).
16. Chen C., Yu R., Owuor E. D., Kong A. N., Arch. Pharm. Res., 23, 605-612 (2000).
17. Deguchi H., Fujii T., Nakagawa S., Koga T., Shirouzu K., Int. J. Oncol., 21, 1301-1305 (2002).
18. Park J. W., Choi Y. J., Suh S. I., Kwon T. K., Biochem. Biophys. Res. Commun., 286, 721-725 (2001).
19. Balasubramanian S., Efimova T., Eckert R. L., J. Biol. Chem., 277, 1828-1836 (2002).
20. Vergote D., Cren-Olivé C., Chopin V., Toillon R.-A., Rolando C., Hondermarck H., Bourhis X. L., Breast Cancer Res. Treat., 76, 195-201 (2002).
21. Pelletier H., Millot J. M., Bruno C., Manfait M., Genne P., Martin F., Cancer Res., 50, 6626-6631 (1990).
22. Boldt S., Weidle U. H., Kolch W., Carcinogenesis, 23, 1831-1838 (2002).
23. Park H. J., Kim B. C., Kim S. J., Choi K. S., Hepatology, 35, 1360-1371 (2002).